Loading clinical trials...

Product Surveillance Registry | Clinical Trials | Clareo Health

RECRUITING

Product Surveillance Registry

Medtronic Product Surveillance Registry

NCT01524276•Medtronic

Summary

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
•Patient has or is intended to receive or be treated with an eligible Medtronic product
•Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment

Exclusion Criteria

•Patient who is, or will be, inaccessible for follow-up
•Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results

Locations (389)

Birmingham, Alabama, United States

Huntsville, Alabama, United States

Chandler, Arizona, United States

Phoenix, Arizona, United States

Little Rock, Arkansas, United States

Aliso Viejo, California, United States

Chula Vista, California, United States

Colton, California, United States

La Jolla, California, United States

Los Angeles, California, United States

Key Dates

Start Date

January 1, 2012

Primary Completion Date

January 1, 2040

Completion Date

January 1, 2040

Last Updated

February 18, 2026

Enrollment

100,000

ESTIMATED participants

Conditions

Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersDigestive DisordersIntracranial AneurysmMechanical Circulatory SupportRespiratory TherapyAortic, Peripheral Vascular and Venous DisordersMinimally Invasive Surgical ProceduresDiagnostic Techniques and ProceduresSurgical Procedures, OperativeRenal InsufficiencyNeurovascularCoronary Artery DiseaseEar, Nose and Throat Disorder

Contacts

Medtronic Product Surveillance Registry

CONTACT

rs.productsurveillanceregistry@medtronic.com

Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.

NCT06975605

Tuberous Sclerosis Complex (TSC)Focal Cortical Dysplasia+1 more

View study

COMPLETED

Prevalence of Visual Dysfunction in Neurological Disorders

NCT04836715

Parkinson DiseaseOther Neurological Disorders+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Product Surveillance Registry

Inclusion Criteria

Exclusion Criteria

Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.

Prevalence of Visual Dysfunction in Neurological Disorders

Oregon Center for Complementary and Alternative Medicine in Neurological Disorders